Melanotan II raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-10. Anything still debated is marked as such rather than presented as settled.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
==== Amidation ==== HA can be conjugated with polymers and probes at the carboxyl group using an amidation reaction involving 1-ethyl-3-[3-(dimethylamino)-propyl]-carbodiimide (EDC) and N-Hydroxysuccinimide (NHS). This reaction occurs in water and is used to form more hydrolysis-resistant, non-rearrangeable intermediates that prevent the formation of the irreversible N-acyl urea byproduct, preventing amide bond formation. The amide group in this reaction can also be modified to contain a thiol group, which allows thiols to be covalently linked to HA. Thiol modification can improve many HA properties such as biocompatibility, permeation, and sustained release of a drug. This is because in the presence of biological components, thiols display a great amount of chemo-selectivity and ability to cross-link.
Sarcosine, also known as N-methylglycine, or monomethylglycine, is a non-proteinogenic amino acid with the formula CH3N(H)CH2CO2H. It is the N-methyl derivative of glycine, with a secondary amine in place of the primary amine, and occurs naturally in muscles and other body tissues as an intermediate in the metabolism of choline to glycine. It was first isolated and named by the German chemist Justus von Liebig in 1847. Sarcosine is ubiquitous in biological materials. It is used in manufacturing biodegradable surfactants and toothpastes as well as in other applications. It is also a reagent in organic synthesis. It has a mildly sweet taste. Pharmacologically, sarcosine functions as a competitive inhibitor of the glycine transporter type 1 (GlyT1), a co-agonist at the glycine binding site of the NMDA receptor, and, at higher concentrations, an agonist at the strychnine-sensitive glycine receptor. These properties have led to its investigation as an adjunctive treatment in schizophrenia and major depressive disorder. Sarcosine has also been identified as an oncometabolite in prostate cancer, where elevated levels correlate with disease progression and metastatic potential.
=== Reconstitution === Perhaps the most extreme of treatments is "reconstitution", wherein fragments of fine turquoise material, too small to be used individually, are powdered and then bonded with resin to form a solid mass. Very often the material sold as "reconstituted turquoise" is artificial, with little or no natural stone, made entirely from resins and dyes. In the trade reconstituted turquoise is often called "block turquoise" or simply "block".
In addition to serving as markers, the linoleic and arachidonic acid products can contribute to tissue and/or DNA damage but also act as signals to stimulate pathways which function to combat oxidative stress.
(Sophy) Mr Crickson – Also known as Creaky to the foster boys: Fast Forward, Waddles, Swap-Out and Demon. He runs a farm and takes in foster boys to do manual labor such as tobacco cutting, barn repair and tending cattle. He treats the boys just well enough for the Department of Social Services (DSS) to allow him to continue to conduct foster care. (Mr. Creakle) Mr and Mrs McCobb – Parents of the foster home where Demon stays after Creaky's. Demon sleeps in the laundry room, which used to be where the dog was kept, and is expected to help pay his way by helping Mr McCobb stuff envelopes; Mr McCobb eventually finds Demon a job at Golly's Market where he sorts trash for cans, bottles and other things of value. The McCobb family is perpetually out of money and takes Demon in only for the money from DSS. (Wilkins Micawber and Emma Micawber) Betsy Woodall – Paternal grandmother who shows up on the day of Demon's birth, wanting to take him with her. After escaping the foster system, Demon seeks her out. She finds a home for Demon with Coach Winfield and his daughter Angus. (Betsey Trotwood) Brother Dick – Betsy’s physically disabled brother. He writes Shakespeare quotes on a huge kite. Demon eventually takes him out in his wheelchair to fly it. (Mr. Dick) Coach Winfield – Demon lives with him while in high school where Winfield is the celebrated football coach of the Generals. (Mr Wickfield) Angus – Coach Winfield's daughter; she and Demon have a relationship that Demon eventually recognizes as something that can last. (Agnes Wickfield) Ryan Pyles – Also known as U-Haul.
Sources: en.wikipedia.org
== Applications == As of 2021 no DNA vaccines have been approved for human use in the United States. Few experimental trials have evoked a response strong enough to protect against disease and the technique's usefulness remains to be proven in humans. A veterinary DNA vaccine to protect horses from West Nile virus has been approved. Another West Nile virus vaccine has been tested successfully on American robins. DNA immunization is also being investigated as a means of developing antivenom sera. DNA immunization can be used as a technology platform for monoclonal antibody induction.
== Adverse effects == Adverse effects of clorazepate include tolerance, dependence, withdrawal reactions, cognitive impairment, confusion, anterograde amnesia, falls in the elderly, ataxia, hangover effects, and drowsiness. It is unclear whether cognitive deficits resulting from the long-term use of benzodiazepines return to normal or persist indefinitely after withdrawal from benzodiazepines. Benzodiazepines are also known to cause or worsen depression. Paradoxical effects including excitement and paradoxical worsening of seizures can sometimes result from the use of benzodiazepines. Children, the elderly, individuals with a history of alcohol use disorder or a history of aggressive behavior and anger are at greater risk of developing paradoxical reactions to benzodiazepines. In September 2020, the U.S. Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of non-medical use, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.
== Contraindications == A person should not receive alteplase treatment if testing shows they are not suffering from an acute ischemic stroke or if the risks of treatment outweigh the likely benefits. Alteplase is contraindicated in those with bleeding disorders that increase a person's tendency to bleed and in those with an abnormally low platelet count. Active internal bleeding and high blood pressure are additional contraindications for alteplase. The safety of alteplase in the pediatric population has not been determined definitively. Additional contraindications for alteplase when used specifically for acute ischemic stroke include current intracranial hemorrhage and subarachnoid hemorrhage. Contraindications for use of alteplase in people with a STEMI are similar to those of acute ischemic stroke. People with an acute ischemic stroke may also receive other therapies including mechanical thrombectomy.
The player's main method of defeating guests is with Combat pages, items used to attack and defend in combat through predetermined actions. The number of Combat Pages usable in a single Scene is equal to the number of Speed Dice a character has. Attacks deal both physical and stagger damage, affecting characters' HP and SR respectively. If a character's SR reaches zero, they will be unable to move and receive fatal damage from all attacks until their SR resets the next turn. A character dies (for the ongoing reception) if their HP reaches 0. Upon starting the Scene, all characters' Speed dice will randomly roll a low or high number or value, determining its Speed and the order of characters' actions. Librarians can redirect Combat pages towards them if they possess higher Speed than their target. Most characters (except bosses) start a reception with 1 or 2 Speed dice. If a librarian redirects a Combat page or opposes a Combat page directed at them, they enter a clash where both sides' Combat pages' actions interact with each other. Two dice will roll and the highest value will act; if both dice roll the same value, actions will be canceled out. Else, the attack counts as a one-sided action where attacks are not opposed. The player needs to carefully manage available resources, namely 'Light' (a form of combat stamina) and Combat pages, which return into the deck to be randomly picked upon usage. If the librarian's current Light is lower than the cost of any available Combat page, or if the librarian has no Combat pages to initiate action, they will be unable to act.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.